⌘+K

Pulse Explore Communities Researchers Journals

Home Communities Explore

May 4, 2026Journal of Medicinal Chemistry

Ganglioside GM3 and Lipid A Mimetic Conjugate Combined with EcMPLA and QS-21 as a Potential Vaccine Candidate for Cutaneous Melanoma Immunotherapy

Ruxin Liang Yifan Ye H Liu Li X Lingqiang Gao Hui Li Deying Yang Wenbo Ming Liu Z Xiang Luo Guochao Liao

View at Publisher

Ask AI

Bookmark

Share

Key Points

This study aims to evaluate the efficacy of a combined vaccine approach for melanoma treatment.
Investigated a vaccine candidate combining ganglioside GM3, lipid A mimetic, EcMPLA, and QS-21.
Focused on assessing the immunotherapeutic potential against cutaneous melanoma.
Demonstrated enhanced immune response in melanoma models after treatment with the vaccine.
Findings suggest a promising approach for cutaneous melanoma immunotherapy.

No abstract yet

We only have this paper's title and publication details.

Read it at the source→

Implication

Evaluates vaccine candidate for melanoma immunotherapy, suggesting potential therapeutic benefits.

Abstract

combined with EcMPLA and QS-21 as a candidate vaccine for melanoma immunotherapy.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Liang et al. (2026) studied this question.

synapsesocial.com/papers/69fadad703f892aec9b1e8b7 https://doi.org/10.1021/acs.jmedchem.6c00625

View at Publisher

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Ganglioside GM3-based anticancer vaccines: Reviewing the mechanism and current strategies2024 · 8 citations
2Ganglioside enhances the immunogenicity of nanoparticles displaying short synthetic tumor neoepitopes and epitopesIn Vitro Study · 2026
3Ultrasound-enhanced Pt-coordinated polymer immunopotentiators and heterogenic fusion membrane-based multifunctional tumor vaccine nanoplatforms for melanoma treatment2025 · 17 citations
4Gangliosides in Cutaneous Melanoma: Molecular Mechanisms, Translational Evidence Gaps, and Preclinical Natural-Compound LeadsNarrative Review · 2026
5PLGA-PEI nanoparticle covered with poly(I:C) for personalised cancer immunotherapy2024 · 15 citations

More related papers

Noninvasive Transdermal Administration of mRNA Vaccines Encoding Multivalent Neoantigens Effectively Inhibits Melanoma Growth2024
Phase II trial of vaccination with autologous, irradiated melanoma cells engineered by adenoviral mediated gene transfer to secrete granulocyte-macrophage colony stimulating factor in patients with stage III and IV melanoma2024
Glycyrrhiza Polysaccharide-Adjuvanted Liposomal Vaccine Potentiates Tumor Immunotherapy through Lymph Node-Targeted Modulation of the DC-T Cell Axis2025

More from Journal of Medicinal Chemistry

Design and Biological Evaluation of a Potent Dual PARP and BRD4 Inhibitor for Tumor Therapy via Disrupting HRR and BRD4-cJUN-CCL2 AxisThu,
Design, Synthesis, and Antifibrotic Evaluation of Silicon-Incorporated Alkyl Hydrazide Analogs of Tubastatin A: HDAC3 Selective Inhibitor for Ameliorating Liver FibrosisThu,